Abstract | Acute anterior uveitis (AAU) and the spondyloarthritis (SpA) subtypes ankylosing spondylitis, reactive arthritis and psoriatic arthritis are among the inflammatory diseases affected by the biology of the intestinal microbiome. In this Review , the relationship between AAU, SpA and the microbiome is discussed, with a focus on the major SpA risk gene HL A-B*27 and how it is associated with both intestinal tolerance and the loss of ocular immune privilege that can accompany AAU. We provide four potential mechanisms to account for how dysbiosis, barrier function and immune response contribute to the development of ocular inflammation and the pathogenesis of AAU. Finally , potential therapeutic avenues to target the microbiota for the clinical management of AAU and SpA are outlined.
1
. The Human Microbiome Project was funded in 2007 by the NIH to characterize the bacteria that are the main constituents of the microbiome 2 . In Europe, a similar project is called Meta Hit 3 . There are at least as many microbial cells as human cells that colonize the body 4 , and their DNA collectively encodes >100-fold as many unique genes as the human genome 5 . From the initial link between the intestinal microbiome and inflammatory bowel disease (IBD), it is increasingly evident that the microbiome is also involved in the pathogenesis of an array of extraintestinal immune-mediated diseases 6 as well as diseases not typically considered to be immune-mediated, such as autism 7 and depression 8 . One such extraintestinal disease is uveitis. In this Review, we discuss links between the intestinal microbiota and the development of uveitis and the family of related diseases known collectively as seronegative spondyloarthritis (SpA), each of which includes uveitis as a potential manifestation.
Uveitis
Uveitis is inflammation of the uvea, which consists of the iris, ciliary body and choroid. Inflammation of the uvea is often accompanied by evidence of inflammation in adjacent structures such as leukocytes in the anterior chamber or in the vitreous humour. Uveitis is the fourth leading cause of acquired blindness [9] [10] [11] and has a point prevalence of approximately 1 person per 1,000 (ref.
12
). Because the disease affects many patients for decades, it causes years of visual loss -as many years of visual morbidity as diabetes or macular degeneration 11 . Uveitis can be subtyped by the portion of the uveal tract that is inflamed ( fig. 1 ). Anterior uveitis is much more common than intermediate uveitis, posterior uveitis or panuveitis, accounting for ~85% of all cases of uveitis 12 .
In one referral series of patients with anterior uveitis, nearly three out of four patients had an acute or sudden onset of disease (acute anterior uveitis (AAU), as opposed to an insidious onset) 13 . AAU is the phenotype typically associated with HLA-B27 (ref.
14 ). In a study from London, UK, 50% of individuals with AAU were found to be HLA-B27-positive 15 . Conversely, uveitis associated with HLA-B27 is typically acute in onset, predominantly anterior and unilateral 14, 16 . HLA-B27-associated uveitis is the most common uveitis diagnosis in many referral centres throughout the world 17 , including Europe 18 , North America 17 , Australia 19 and parts of southeast Asia 20, 21 . In addition, HLA-B27-associated uveitis is often undiagnosed 22, 23 , and consequently its association with SpA can be overlooked. All forms of SpA including ankylosing spondylitis, reactive arthritis, psoriatic arthritis and arthritis associated with IBD can cause sacroiliitis, peripheral arthritis, enthesitis and uveitis. HLA-B27 affects the susceptibility to uveitis in each of these subtypes of SpA 14, 16, 24 . Other genetic, environmental and stochastic factors also contribute to the development of AAU and SpA (Box 1) . The fact that 50% of patients with AAU are HLA-B27-negative indicates that these factors are well worth studying, but they are not the focus of this Review.
Uveitis has a broad differential diagnosis that includes immune-mediated systemic diseases, immune-mediated syndromes confined to the eye, infections (including fairly common infections such as herpes simplex, herpes zoster and toxoplasmosis and fairly rare infections such as Lyme disease and Whipple disease), masquerade syndromes such as lymphoma and adverse reactions to medications 25 . Although many forms of 2) ; uveitis is the most common clinically important comorbidity diagnosed in patients with ankylosing spoindylitis, affecting as many as 50% of patients in some studies 26, 27 , 7-19% of patients with psoriatic arthritis 24, 28 and only ~2% of patients with IBD 29, 30 . The much higher likelihood of uveitis occurring in the setting of ankylosing spondylitis as opposed to psoriatic arthritis or IBD is consistent with HLA-B27 acting as a major risk factor as this gene is much more associated with ankylosing spondylitis than other forms of SpA 16 . Molecular mechanisms that link joint disease and uveitis are unclear, but these diseases coexist in several animal models, with uveitis occurring in models of adjuvant-induced arthritis in rats 31 , aggrecan-induced arthritis in BALB/c mice 32 and the SKG mouse model of arthritis (the SKG model being dependent on a mutation in the gene encoding tyrosine-protein kinase ZAP70 plus challenge with a ligand that activates the innate immune system such as curdlan, a mannan that can be a fungal cell wall component) 33 . Arguably the most popular animal for studying HLA-B27-associated disease is the HLA-B27-transgenic rat, which typically develops spondylitis, peripheral arthritis, colitis and dermatitis but not uveitis 34 . Although the reasons for a lack of uveitis in this rat are not clear, humans can also develop ankylosing spondylitis without uveitis, and the cause of HLA-B27-associated uveitis is clearly multifactorial.
The intestinal link to SpA and uveitis A diverse number of tissues may be sites of inflammation across the SpA disease spectrum ( fig. 3) , one of which is the intestine. Some of the first evidence to establish a link between SpA and intestinal inflammation was from histological analysis of tissue obtained during colonoscopy as a research study of patients with SpA and no overt intestinal symptoms, in which more than half of patients exhibited subclinical or unrecognized inflammation 35, 36 . Patients with ankylosing spondylitis can have increased intestinal permeability 37 . A variety of enteric infections with bacterial genera including Salmonella, Yersinia, Shigella and Campylobacter can trigger reactive arthritis 38, 39 . The efficacy of sulfasalazine for peripheral joint disease associated with SpA might derive from its known effects on the intestinal microbiota and the ability to reduce intestinal permeability 40, 41 . Crohn's disease and ulcerative colitis are thought to be caused by changes in the microbiome [42] [43] [44] [45] , and an altered microbiome is a feature of patients with ankylosing spondylitis [46] [47] [48] , psoriatic arthritis 49 and juvenile-onset enthesitis-related arthritis [50] [51] [52] . Studies of the faecal microbiome are limited in value as faecal samples might not represent the bacterial ecosystem at a critical site, such as the mucosa of the caecum. The faecal sample is also affected by many variables such as disease duration or factors that do not necessarily relate to the disease of interest, including age, medications ingested, sex, diet and geographical location. Furthermore, differences in the microbiome do not always indicate a mechanism of pathogenesis, as such changes might result from the disease. Despite these limitations, comparing the faecal microbiome of patients with or without disease is usually one of the first experimental studies to implicate the microbiome in rheumatic disease, as an absence of difference in the microbiome of patients compared with healthy individuals would imply that the microbiome is not an important factor in causation of the disease.
Key points
• Acute anterior uveitis (AAu) is the most common, clinically apparent, extra-articular manifestation of ankylosing spondylitis.
• Both AAu and ankylosing spondylitis are strongly associated with HlA-B27.
• HlA-B27 affects the composition of the gut microbiome, which in turn can modify the immune system and thereby affect health and disease.
• The intestinal microbiome is strongly implicated in the pathogenesis of AAu and ankylosing spondylitis. HLA molecules and the microbiome HLA molecules affect susceptibility to >100 diseases 53 , and although they regulate the immune response, the mechanism by which these molecules predispose an individual to most diseases is not known. The association between HLA-B27 and SpA is among the strongest relationships between an HLA allele and a disease. MHC genes such as HLA genes in humans are the most polymorphic genes known 54 . A teleological perspective is that the immune response is primarily a defence against infection and that polymorphism minimizes the probability that a specific infection could eradicate a species. A corollary to this idea is that the HLA genotype should affect the bacterial composition of the gut.
To test this hypothesis that HLA molecules would affect the intestinal bacterial composition, the microbiome of HLA-B27-transgenic rats that express multiple copies of HLA-B27 along with the invariant MHC light chain, β 2 -microglobulin, was compared with the microbiome of littermate controls 55, 56 . These studies indicate clearly that expression of the human MHC molecule with its invariant light chain results in an alteration of microbiota in the intestine. The SpA-like disease that affects these rats was first described by Hammer et al. more than two decades ago 57 . HLA-B27-transgenic rats on a Fischer 344 background develop diarrhoea around 2-4 months of age. Subsequently, many of these rats develop psoriasiform rashes, peripheral arthritis and spondylitis 53 . The microbiome is an important contributor to this disease, because if the rats are raised in a germ-free environment, intestinal and joint disease is reduced 58 . Some bacteria such as Lactobacillus rhamnosus GG can be given by oral gavage such that remission is maintained, whereas other bacteria can cause the disease to recur 59 . As noted above, the intestinal microbiome is altered by the expression of HLA-B27 in these transgenic rats 55, 56 . Evidence indicates that other HLA alleles can also modify the composition of the microbiota. MHC molecules that predispose to coeliac disease alter the intestinal microbiome of infants 60 . The HLA-DR*0401 allele, which predisposes to rheumatoid arthritis, alters the microbiome in transgenic mice in comparison to those that are transgenic for HLA-DR*0402 (ref.
61
). Transgenic expression of human MHC class II molecules can protect mice from the development of autoimmune diabetes 62 , and the faecal microbiome of these animals protects non-obese diabetic (NOD) mice from developing hyperglycaemia. These studies complement those that more broadly show that the host MHC haplotype affects the composition of the microbiota 45 .
HLA-B27 modification of intestinal microbiota
A number of host mechanisms that regulate composition of the microbiota are perturbed in the presence of HLA-B27. Although how HLA-B27 might modulate them directly is unknown, they may be major events in the dysbiosis and loss of intestinal homeostasis that are proposed to accompany SpA and AAU.
One of the first detectable immunological changes in HLA-B27-transgenic rats is the increased intestinal synthesis of antimicrobial peptides (AMPs) such as regenerating islet-derived protein 3γ (RegIIIγ) and protein S100A8 (also known as calprotectin) 63 . In light of their bactericidal activity, AMPs are known to potently modify composition of the intestinal microbiota 64 . Interestingly, serum calprotectin has been reported to be a biomarker for posterior uveitis 65 , juvenile idiopathic arthritis with uveitis 66 and Behçet disease 67 . Synthesis of mucus, a major substrate of the microbiota, is increased in HLA-B27-transgenic rats 68 and an expansion of Akkermansia muciniphila, a microorganism that metabolizes mucus, is detected in this model 55 . This microorganism has been shown to promote ankle swelling subsequent to oral gavage in the K/B × N mouse model of arthritis 69 , but its role in uveitis remains to be established. The relationship of this specific microorganism with HLA-B27 expression is probably complex, however, as its colonization has been reported to be variably increased or decreased in patients with HLA-B27-associated SpA 70, 71 . Another major host factor that shapes the intestinal microbiota is secretory immunoglobulin A (IgA) (reviewed in ref. 72 ), which may be modulated in the presence of HLA-B27. For example, it has been shown that there is a higher frequency of IgA-coated bacteria in the faeces of HLA-B27 transgenic rats versus wild-type controls and a higher frequency in arthritic versus non-arthritic animals 63 . By contrast, a study of patients (which grouped reactive arthritis and undifferentiated SpA together) reported no difference in secretory IgA on the basis of HLA-B*27 status 73 but did detect a negative correlation between disease activity and serum IgA concentration that was stronger in HLA-B27-positive individuals than in those who were HLA-B27-negative. The discrepancy between these studies perhaps reflects tissue-specific or species-specific differences that are yet to be resolved.
It should be stressed that pathways such as AMP production, mucus synthesis or IgA production that may be affected by HLA-B27 expression have mostly been shown to be dysregulated in animal models or humans that have already developed intestinal inflammation or individuals who may have had subclinical, focal or transient intestinal inflammation that is difficult to detect 68, 69, 73 . As all of these homeostatic mechanisms are modulated by inflammation and affect microbiota composition, whether these changes precede immune disturbance and intestinal dysbiosis will require careful examination to establish whether they are primary events in the pathogenesis of HLA-B27-associated SpA and AAU.
Further to recent recognition that HLA-B27 might modify the intestinal microbiota, several major mechanisms through which this haplotype might contribute to HLA-B27-dependent AAU (and SpA) have been proposed. Evidence for and against each have been extensively reviewed previously 74 . In brief, the mechanisms are: HLA-B27-restricted antigen presentation; the property of HLA-B27 to misfold and accumulate in the cytoplasm, which may dysregulate homeostatic cellular responses such as the unfolded protein response (UPR) or autophagy; HLA-B27 homodimer formation triggering activation of natural killer (NK) cell receptors; HLA-B27 expression rendering innate immune cells hyporesponsive to stimulation with microorganisms or microbial products; HLA-B27 not being able to present an antigen to confer protective immunity to a pathogen; and HLA-B27 presenting a bacterial antigen such that there is an enhanced immune response resulting in dysbiosis because of a shift in the intestinal ecosystem.
Each mechanism could conceivably lead to either diminished immune function or inflammation in the intestines that might modify the microbiota. For example, AMP expression has been convincingly linked to UPRs 75 . Another layer of complexity is provided by studies of germ-free animals that show that many homeostatic pathways such as AMP production, mucus synthesis or IgA production are dependent on the microbiota itself [76] [77] [78] , indicative of the ongoing feedback between the host and commensal microorganisms. Therefore, an initial perturbance in a pathway such as mucus production could lead to dysbiotic changes that provoke change in host immunity such as an elevated IgA response that could further modify the intestinal microbiota. The accumulation of these events, or 'runaway dysbiosis' , might lead to the loss of homeostatic pathways that are normally sufficient to prevent microbiota-dependent uveitis.
How might the microbiome contribute to uveitis?
Several models can be proposed in which the intestinal microbiome is an important component of AAU pathogenesis (summarized in fig. 4 ). We stress these models are not mutually exclusive.
First model: loss of microbiota-dependent immune homeostasis. A dysbiotic microbiota could lead to a loss of immune homeostasis and lower the threshold of immune activation such that an innocuous trigger elicits an inflammatory response ( fig. 4a ). This response could include hyperresponsiveness of the innate immune system to microbial-associated molecular patterns (MAMPs) or danger-associated molecular patterns (DAMPs) derived from host cells and the priming and expansion of lymphocytes by antigen-presenting cells that present innocuous antigen in this inflammatory context. As shown in studies of mice, bacteria could regulate the number of transcription factor forkhead box P3 (FOXP3) + cells in peripheral blood 79 , the number of T cells that produce IL-10 (ref.
80
) or the number of T helper 17 (T H 17) cells 81 . A variety of Klebsiella strains cultured from the oral microbiome of a patient with Crohn's disease can induce T H cells in the intestine of a mouse 82 . A reduction in the number of regulatory T (T reg ) cells that are either FOXP3 + or that synthesize IL-10 could predispose to immune-mediated inflammation. Similarly, an increase in T H 17 cells could easily predispose to immune-mediated disease. Experimental autoimmune uveitis (EAU) in mice is a commonly used T cell-dependent model of uveitis that can be induced by immunization with a variety of antigens such as interphotoreceptor retinoid-binding protein (IRBP) in combination with adjuvant. Disease in this mouse model can be ameliorated by depletion of intestinal bacteria with broad-spectrum oral antibiotics 83 . The antibiotic treatment results in an increase in FOXP3 + T cells in the cervical lymph node, mesenteric lymph node, spleen and retina. Similarly, there is a transient increase in the number of T H 17 cells in the cervical lymph node. As these experiments use a model of posterior (not anterior) uveitis, extrapolating these data to AAU should be done with caution.
Second model: molecular mimicry. A bacterial antigen could mimic an autoantigen ( fig. 4b) . Rheumatic fever 84 and Guillain-Barré syndrome 85 are thought to be immune-mediated diseases triggered by bacterial or viral mimicry. Endogenous peptides presented by the HLA alleles that predispose to rheumatoid arthritis have substantial homology to amino acid sequences in bacterial genera including Prevotella, Parabacteroides and Butyricimonas 86 . A single T cell receptor has some NATuRE REvIEws | RhEUmATology , whereas uveitis associated with psoriatic arthritis (PsA) 24 or inflammatory bowel disease (IBD) 16 is more likely to be chronic or posterior to the lens of the eye. plasticity -that is, an ability to recognize diverse peptides, some of which could cross-react with self-peptides 87 . Horai et al. 88 have described a murine model of posterior uveitis mediated by transgenic T cells that recognize the retinal antigen IRBP. In this model, a bacterial antigen from the intestine activates these T cells, presumably through antigenic mimicry 88 . This paradigm of molecular mimicry, however, might not apply to HLA-B27-associated anterior uveitis, for which autoantibodies and autoreactive T cells are not generally considered to be markers of disease. Although mimicry between HLA-B27 and a bacterial antigen has been reported 89, 90 , these reports are >20 years old and still no explanation exists as to the tissue distribution of HLA-B27-related disease.
Third model: translocation of microorganisms or microbial products. A change in intestinal bacteria could alter intestinal permeability (fig. 4c ). This permeability can enable bacterial products to disseminate into the vasculature and tissues and potentially lodge in the synovium or the uvea, where an immune response might be triggered. Data that support this hypothesis come from studies showing that intestinal permeability is increased in patients with ankylosing spondylitis 91 and is accompanied by dysregulated intestinal tight junction expression and translocation of microbial LPS into the vasculature 92 . Within joint tissue, bacterial products have been detected in the synovial fluid of patients with ankylosing spondylitis 93 and reactive arthritis 39, 94 . A study from Tunisia also reported bacterial products in the synovium of six patients with reactive arthritis 95 . Bacterial translocation to the blood has been documented in patients with Crohn's disease 96 , and these patients are more likely to have flares of disease activity than patients without such bacterial dissemination 96 . Gonococcal arthritis is an example in which bacteria can disseminate to the synovium 97 . Increased bacterial cell wall in the form of peptidoglycan has been detected by immunostaining in the joints of patients with rheumatoid arthritis 98 . However, it is important to note that translocation of bacterial products has been detected in healthy individuals who experience an increase in bowel permeability, such as marathon runners 99 . Brushing teeth might also result in bacterial products transiently entering the bloodstream 100 . An intriguing study by Atarashi et al. demonstrated that oral bacteria potentiate inflammatory responses if they colonize the mouse intestine 82 . Moreover, colonization of the liver by the intestinal pathobiont Enterococcus gallinarum might contribute to the pathogenesis of systemic lupus erythematosus 101 . This observation reinforces the idea that if bacteria or bacterial products are outside their normal habitat (for example, translocating to the eye or the joint), they might be aetiological agents of disease (such as uveitis or arthritis, respectively), and similarly microbial products such as LPS or β-glucan might potentiate uveitic inflammation if they are able to deposit in the uveal tract. Tolerance or tachyphylaxis to these microbial products might develop in the intestine. Indeed, given the formidable barriers that contain bacteria within the gut and avoid translocation (such as the gut-vascular barrier 102 ), it might be microbial products rather than live or dead bacteria that reach distal sites such as the eye or the joint.
However, bacterial translocation is probably necessary but not sufficient for arthritis. Bouziat et al. 103 studied an HLA-DQ8-transgenic mouse that is predisposed to coeliac disease. These mice were fed a diet that includes gluten and did not develop features of autoimmune disease; however, after infection with a reovirus that by itself induces no symptoms in the mouse, auto antibodies to transglutaminase were detectable. This paradigm of predisposing genetic and environmental factors still requiring a 'second hit' such as a viral infection suggests that a similar predisposing event is necessary for bacteria to induce arthritis after translocation to a joint or to the eye.
In contrast to the joint, we are not aware of direct evidence that bacterial products are translocated to the anterior uveal tract during non-infectious AAU. However, the adage that absence of evidence does not equate to evidence of absence may be applicable. As the eye is not biopsied (except in rare instances) during acute www.nature.com/nrrheum R e v i e w s 708 | DECEMBER 2018 | voluME 14
Molecular mimicry
The induction of autoimmunity caused by a non-self-antigen, such as one derived from a bacteria or virus, that resembles a self-antigen sufficiently such that an autoimmune response is induced. Spondyloarthritis (SpA) can involve pathology in various parts of the body. SpA-associated inflammation may manifest in diverse tissue sites including the eye (uveitis), the prostate and skin in addition to classical sites such as the spine or joint. Aortic root disease is an uncommon yet serious clinical complication. Red boxes signify that osteoporosis and sarcopenia are important comorbidities that might be associated with the loss of function that accompanies spinal or joint disease.
inflammation, and the amount of fluid available for study from an anterior chamber is limited, studying or detecting bacterial products in the eyes is a challenge. A footpad injection of bacterial endotoxin has been shown to induce AAU in rats 104 . The rodent eye expresses a variety of Toll-like receptors (TLRs) and becomes inflamed after direct injection of bacterial products 105 . TLR2 expression is downregulated on leukocytes from patients with AAU, but these cells produce more IL-1β than leukocytes from healthy controls in response to TLR2 activation 106 . In patients with Crohn's disease, translocation of bacterial products to the blood has been demonstrated 96 ; thus, it is plausible that some bacterial product or products might also disseminate to the anterior uveal tract. In addition, host-derived inflammatory products such as DAMPs might trans locate from the intestine to the eye, where they could also contribute to the local inflammatory cascade (fig. 4c) .
If translocation is a critical component in the pathogenesis of uveitis, it is appropriate to ask why uveitis is not more common in intestinal disease in comparison with ankylosing spondylitis. Although the answer to NATuRE REvIEws | RhEUmATology this question is not known, we offer two hypotheses. First, the increase in permeability in IBD could lead to tachyphylaxis such that bacterial products are constantly exposed to the immune system and thus induce less inflammation. Second, as discussed above, HLA-B27 is the major known genetic factor that predisposes to AAU. As HLA-B27 is not associated with IBD, it makes sense that AAU is less common in IBD.
Fourth model: extraintestinal migration of immune cells. Translocation of lymphocytes or other inflammatory cells from the intestine to the eye ( fig. 4d ) might also account for the role of the intestine in the pathogenesis of AAU. Transgenic mice that express the photoconvertible pigment kaede enable the study of cell trafficking from sites that are experimentally exposed to ultraviolet light such as the colon 107 . Using this approach, unexpectedly broad extraintestinal migration of both myeloid and lymphoid cells to peripheral tissues has been convincingly demonstrated 107 . Using the EAU mouse model, the presence of intestinal-derived CD45 + leukocytes has been detected in the eye 108 , although further immune phenotyping was not performed in this study 108 . Other studies have demonstrated that circulating lymphocytes with presumed intestinal origin (as they are commensal reactive and express gut homing chemokine receptors) are a part of the normal circulating T cell pool, even in healthy individuals 109 . Alternatively, a failure of immune trafficking to the eye might perturb ocular homeostasis, as has been proposed for B cells primed by commensals in the intestine that have been hypothesized to migrate to the lacrimal gland and provide protective immunity to ocular commensals that reside on the surface of the eye 110 . However, the relevance of such a pathway to uveal homeostasis is unclear.
The microbiome also affects multiple populations of non-conventional lymphoid cells that reside in the intestine, including NK cells and other innate lymphoid cells, intraepithelial lymphocytes, γδ T cells and mucosal-associated invariant T cells 74 . Several of these cell types have been implicated in SpA 111, 112 and some (for example, invariant NK T (iNKT) cells and γδ T cells) in models of uveitis 113, 114 .
Clinical implications
Assuming that the microbiome does contribute to HLA-B27-related uveitis and arthritis, the contribution is probably considerable if one extrapolates from what we know about germ-free HLA-B27-positive rats. Future treatment modalities should target the microbiome ( fig. 5) , a goal that might be simplified if a single bacterium could be implicated in HLA-B27-related inflammation, just as Helicobacter pylori was shown to cause gastritis and peptic ulcer disease. However, if no single organism is the cause of HLA-B27-related inflammation, what are the clinical options?
One option is faecal transplantation, an approach that has had success in treating recalcitrant Clostridum difficile infection 115 and ulcerative colitis 116, 117 . Obstacles to faecal transplantation include the aesthetics, safety (as the approach might transmit pathogenic bacteria, prions or viruses such as cytomegalovirus 118 ) and the probability that the effect would be transient, such that frequent repeat transplants would be required.
An alternative approach is to target microbial metabolites or downstream signalling pathways that are known to be altered in HLA-B27 + rats and patients with SpA 32, 83 . For example, fewer short-chain fatty acids (SCFAs) are present in the intestine of HLA-B27 + rats 119 , and oral supplementation with the SCFA propionate reduces inflammation in the caecum and colon. This effect is accompanied by a reduction of important inflammatory cytokines in intestinal tissue, including IL-1β, IL-17 and IFNγ (ref.
119
). In addition, SCFAs can attenuate disease in an inducible model of EAU 108 .
Medications that reduce intestinal permeability could also be effective in preventing the dissemination of bacterial products. Sulfasalazine is an antibiotic combined with a cyclooxygenase inhibitor that reduces intestinal permeability; as noted above, sulfasalazine efficacy might relate, in part, to this effect 40 . Mongersen (also known as GED-0301), a SMAD7 antisense oligonucleotide that antagonizes transforming growth factor-β signalling, is also proposed to ameliorate IBD while reducing intestinal permeability 120 . Most antibiotics are not likely to have a sustained benefit to treat or prevent AAU, as resistance should develop rapidly. Probiotics are a popular option, but little is known about the intestinal bioavailability of probiotics given that the low gastric pH is likely to result in the death of most orally ingested bacteria. Diet can profoundly affect the microbiome and offers what is arguably the best hope to prevent AAU. The challenge is the complexity of diet, which makes it difficult to identify Selective depletion of harmful bacteria or recolonization with benign bacteria, the latter derived from probiotics or faecal microbiota transplant could limit intestinal dysbiosis. Prebiotics might promote the growth of beneficial bacteria. Anti-inflammatory microbial metabolites, such as short-chain fatty acids, might also be used or targeted to treat HL A-B27-associated gut inflammation. Diet is another method to modify the microbiota and, similar to faecal microbiota transplant, may well include both probiotics and prebiotics. Finally , targeting microbiota-associated intestinal permeability might be another way of attenuating HL A-B27-associated inflammatory sequelae.
components that need to be added or subtracted for sustained benefit.
Perinatal exposure to bacteria can have lifelong effects. For example, mice born by Caesarian section have immune system differences that persist into adulthood when compared with animals born transvaginally 121 , and patients with ankylosing spondylitis are reportedly less likely to have been breastfed compared with individuals without the disease 122 . If genetics can identify individuals at high risk of developing SpA, exposure to protective bacteria during infancy might have sustained benefit in the prevention of disease.
In addition to genetic approaches (for example, HLA-B27 genotyping) that can be used to establish disease risk, the composition of the microbiota itself could prove clinically useful even if it cannot be successfully targeted therapeutically. To this end, if dysbiosis is a substantial component of AAU pathogenesis, it might be used to predict disease risk, time of onset, progression or treatment response.
Conclusions
Just a decade ago, the intestinal microbiome was considered a black box. Most of the organisms that comprise the intestinal microbiome are anaerobic and difficult to culture. As the cost of DNA sequencing has fallen, further characterization of the bacteria with which we have a symbiotic relationship is now possible. However, this technological advance is ongoing, and our understanding of the microbiome is incomplete. We believe, however, that the microbiome will ultimately become an essential target in the treatment and prevention of immune-mediated diseases, including uveitis. Given the many links between the microbiome and AAU, we hope that the puzzle as to why HLA-B27 predisposes to this disease will soon be solved.
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